Explore. Learn. Join the conversation.

Working Group on New TB Drugs

Stop TB Partnership

11 Apr 2012

TB R&D Update: Strategies for Early and Late Stage Drug Development

9.cover

This week, we are highlighting two articles published online in the Journal of Infectious Diseases in March. The first article by Coxon, et al., looks at the benefits and limitations of the two main approaches to compound discovery for TB, target-based and phenotypic-based. The second article by Phillips, et al., would like TB clinical trialists to consider new strategies or designs for evaluating TB drug regimens which could alleviate a bottleneck as new drugs and consequently new potential drug combinations move into clinical testing. Additional links to TB R&D publications and news are included.

29 Mar 2012
by Working Group

Posted in Announcements, TB Drug Development, TB News

Working Group on New TB Drugs Launches Strategic Plan 2011-2015

Click here to access publication.

The WGND Strategic Plan 2011-2015 is an update of the “New Drugs” section of the Global Plan to Stop TB: 2011-2015. It describes the progress, gaps, and vision of the WGND and the TB drug development field as a whole.

27 Mar 2012

TB R&D Update: 243rd American Chemistry Society Conference

acs-logo

The 243rd American Chemistry Society National Meeting and Exposition is being held in San Diego, California, from March 26 to March 29. There are several presentations on tuberculosis. Here are the abstracts of a few of the talks. The first item received news coverage and discusses two approved antibiotics that may prove effective in treating TB. Additional links to TB R&D News are included.

23 Mar 2012
by Working Group

Posted in Action, Announcements, Events, TB News

World TB Day! Overview of Events, News and Messages

wtd2012

Saturday, March 24, is officially World TB Day but there has been a stream of activities, publications, news and messages to let the world not forget about this major infectious disease killer that claims millions of lives each year. We present links and summaries of events, publications, messages, and news coverage leading up to World TB Day.

9 Mar 2012

TB R&D Weekly Update: Results from Preventative Therapy Trial in SA Miners

Thibela-Combined-Logo

At the 19th Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, results on the Thibela TB preventative therapy trial in South Africa gold miners was presented with mixed outcomes. Additional links to TB R&D news are included.

TB R&D Weekly Update: Podcast Interview with Dr. Tawanda Gumbo

Tawanda_Gumbo.27720418_std

In this week’s interview, we discuss with Dr. Tawanda Gumbo his recently published paper that puts forth evidence that nonadherence may not be the prime reason for the emergence of drug resistance in TB, his research interests and background, the recent debate on the role of efflux pumps in drug tolerance and his research to optimize TB drugs. Additional links to TB R&D news are included.

23 Feb 2012

TB R&D Weekly Update: CSU Identifies Anti-TB Compound against Unique Target

ncb feb2012

This week’s article highlights research out of Colorado State University that identifies a potential anti-TB compound against a unique target– the inner membrane transporter MmpL3 of Mycobacterium tuberculosis–that inhibits an essential cell function of the mycobacteria. Additional links to TB R&D News are included.

TB R&D Weekly Update: Tailoring TB Treatment Based on Host Genotype?

cell feb2012

This week we have research out of the Ramakrishnan Laboratory that challenges thinking around tuberculosis treatment and considerations of host genotypes. Additional links to TB R&D news are included.

27 Jan 2012
by Working Group

Posted in Announcements, Events, TB Drug Development, TB News

Summary Available! TB Clinical Trials Consultants Meeting

Businesswoman Talking During Meeting

On November 17 and 18, a TB Clinical Trials Consultants Meeting was held at St. George’s, University of London. The meeting was organized by CDC, CPTR, INTERTB, NIH, and TB Alliance. The meeting was convened to catalog expert opinion on the conduct of Phase 2 and Phase 3 clinical trials in tuberculosis.

26 Jan 2012
by Working Group

Posted in TB Drug Development, TB News

TB R&D Weekly Update: SQ109 and PNU Compounds Additive

JAC cover

In this week’s article, we look at two drugs in our Global TB Drug Pipeline and how they interact with each other: SQ109 (class: Ethylenediamines, Sequella) and PNU-100480 (called Sutezolid, class: Oxazolidinone, Pfizer). Additional links to TB R&D news are included.